DURATION-4: Improvements in glucose control and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide once weekly, metformin, pioglitazone, or sitagliptin

被引：0
|
作者：
Boardman, M. K. [1 ]
Hanefeld, M. [2 ]
Kumar, A. [3 ]
Gonzalez, J. G. [4 ]
de Teresa, L. [5 ]
Northrup, J. [1 ]
Chan, M. [1 ]
Russell-Jones, D. [6 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Tech Univ Dresden, Ctr Clin Studies, Dresden, Germany
[3] Diabet Care & Res Ctr, Patna, Bihar, India
[4] Univ Hosp, Serv Endocrinol, Monterrey, Mexico
[5] Clin Mediterranea Neuroci, Alicante, Spain
[6] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford, Surrey, England
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
779
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
    Russell-Jones, David
    Cuddihy, Robert M.
    Hanefeld, Markolf
    Kumar, Ajay
    Gonzalez, Jose G.
    Chan, Melanie
    Wolka, Anne M.
    Boardman, Marilyn K.
    DIABETES CARE, 2012, 35 (02) : 252 - 258
  • [2] Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    Bergenstal, Richard M.
    Wysham, Carol
    MacConell, Leigh
    Malloy, Jaret
    Walsh, Brandon
    Yan, Ping
    Wilhelm, Ken
    Malone, Jim
    Porter, Lisa E.
    LANCET, 2010, 376 (9739): : 431 - 439
  • [3] Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes
    Diamant, M.
    Van Gaal, L. F.
    Stranks, S. N.
    Northrup, J.
    Cao, D.
    Taylor, K.
    Trautmann, M.
    DIABETOLOGIA, 2010, 53
  • [4] Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients with Type 2 Diabetes
    Cuddihy, Robert M.
    Russell-Jones, David
    Hanefeld, Markolf
    Kumar, Ajay
    Gonzalez, Jose G.
    de Teresa, Luis
    Boardman, Marilyn
    Chan, Melanie
    Wolka, Anne M.
    Porter, Lisa
    DIABETES, 2011, 60 : A77 - A77
  • [5] Effects of Exenatide Once Weekly plus Dapagliflozin, Exenatide Once Weekly, or Dapagliflozin Added to Metformin Monotherapy on Cardiovascular Risk Markers in Patients with Type 2 Diabetes in the DURATION-8 Study
    Jabbour, Serge A.
    Frias, Juan P.
    Guja, Cristian
    Hardy, Elise
    Ahmed, Azazuddin
    Ohman, Peter
    DIABETES, 2017, 66 : A307 - A307
  • [6] DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
    Blevins, Thomas
    Pullman, John
    Malloy, Jaret
    Yan, Ping
    Taylor, Kristin
    Schulteis, Christine
    Trautmann, Michael
    Porter, Lisa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05): : 1301 - 1310
  • [7] Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients with Type 2 Diabetes
    Horton, Edward
    Taylor, Kristin
    Porter, T. K. Booker
    Han, Jenny
    Wilhelm, Ken
    Harris, Carmen
    DIABETES, 2010, 59 : A163 - A163
  • [8] Safety of Exenatide Once Weekly in Patients with Type 2 Diabetes Treated with a Thiazolidinedione
    Norwood, Paul
    Pintilei, Ella
    Pop, Lavinia
    Liutkus, Joanne
    Choi, Suktae
    Giaconia, Joseph
    Trautman, Michael
    DIABETES, 2010, 59 : A195 - A195
  • [9] Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years
    Norwood, Paul
    Liutkus, Joanne F.
    Haber, Harry
    Pintilei, Ella
    Boardman, Marilyn K.
    Trautmann, Michael E.
    CLINICAL THERAPEUTICS, 2012, 34 (10) : 2082 - 2090
  • [10] Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David
    Trautmann, Michael
    Zhuang, Dongliang
    Porter, Lisa
    DIABETES, 2008, 57 : A33 - A33
12345